Accessibility Menu
NanoViricides logo

NanoViricides(NYSEMKT) NNVC

Current Price$1.67
Market Cap$40.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-89%
5 Year-60%
1 Year+4%
1 Month+25%
NanoViricides last closing stock price
MetricPriceDate
Last closeUSD 1.752026-07-20
NanoViricides stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.06%USD 1.652026-07-13
1 month+25%USD 1.402026-06-18
3 month+38.89%USD 1.262026-04-21
Year to date+54.87%USD 1.132025-12-31
1 year+4.17%USD 1.682025-07-18
3 year+8.02%USD 1.622023-07-21
5 year-59.86%USD 4.362021-07-21
Since inception-88.64%USD 15.402005-06-02

NanoViricides Financials at a Glance

Market Cap

$40.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$8.09M

EPS (TTM)

-$0.44

P/E Ratio

-4.02

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$1.67

Volume

104,885.348

Open

$1.75

Previous Close

$1.75

Daily Range

$1.67 - $1.79

52-Week Range

$0.85 - $2.23

Estimated Earnings Date

Sep 2, 2026

NNVC News

Image8

Could These 3 Biotechs Help Fight the MERS Virus?

Leo SunMay 17, 2014

5 of Last Week's Biggest Losers

Rick MunarrizFeb 16, 2014

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NanoViricides

NanoViricides develops experimental drugs to fight viral infections like COVID-19 and herpes. Its products aim to help patients with hard-to-treat viral diseases. The company focuses on creating new treatments for people with limited options.

Lab Bench to Bedside: What NanoViricides Makes

  • NV-387: Lead antiviral drug candidate for coronaviruses, influenza, RSV, smallpox, and measles. No revenue contribution yet.
  • HerpeCide Program: Topical, eye drop, and injection drugs for herpes-related diseases. No revenue contribution yet.
  • FluCide: Injectable and oral drugs for influenza, targeting both hospitalized and outpatient cases. No revenue contribution yet.
  • DengueCide: Drug candidate for dengue virus infections. No revenue contribution yet.
  • HIVCide: Experimental drug for HIV, designed to resist viral mutation. No revenue contribution yet.

Plot Twists: Growth Moves and Strategic Steps

  • Advanced NV-387 into Phase I human trials in 2024; no adverse events reported.
  • Received approval in 2025 from the Democratic Republic of Congo for Phase II MPox trial.
  • Expanded in-house manufacturing in 2025, adding oral gummies production equipment.
  • Signed a Memorandum of Understanding with TheraCour Pharma in 2024 for future antiviral rights.
  • Out-licensing agreement with Karveer Meditech in India for NV-CoV-2 clinical development.

Why NanoViricides Is a Bit Different

NanoViricides uses a proprietary technology that mimics human cells to block viruses. Its in-house manufacturing allows for quick drug production and testing. The company holds exclusive licenses for several viral disease treatments.

Five Things You Need to Know

  • Revenue was $0 in QQ4 2025, unchanged from QQ4 2024 and QQ4 2023.
  • Net loss was $2M in QQ4 2025, improving 11.5% from QQ4 2024.
  • Cash and cash equivalents were $2.5M as of March 31, 2025.
  • Operating expenses rose to $7.5M for the nine months ended March 31, 2025, up approximately 22% year-over-year.
  • Accumulated deficit reached $146.7M as of March 31, 2025.

Bottom Line

NanoViricides remains a research-focused company with no product sales and ongoing losses. Its future depends on advancing drug candidates and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Anil R. Diwan, PhD

Website

www.nanoviricides.com

Headquarters

Shelton, CT 06484, US

NNVC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-92.69%

Return on Capital

-127.59%

Return on Assets

-79.18%

Earnings Yield

-24.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$40.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.98M

Volume

104.89K

Avg. Volume

941.15K

Financials (TTM)

Gross Profit

-$129.63K

Operating Income

-$8.18M

EBITDA

-$7.53M

Operating Cash Flow

-$7.28M

Capital Expenditure

-$94.51K

Free Cash Flow

-$7.37M

Cash & ST Invst.

$3.21M

Total Debt

$0.00

NanoViricides Performance Analysis

NanoViricides annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
20252025-06-30USD 0N/A
NanoViricides sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
NanoViricides annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.70N/A
20232023-06-30USD -0.745.1%
20242024-06-30USD -0.70-5.4%
20252025-06-30USD -0.63-10.4%
NanoViricides sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-307.1%
Q12025-09-3023.1%
Q22025-12-31-10.0%
Q32026-03-3116.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$129.63K

N/A

Gross Margin

0.00%

N/A

Market Cap

$40.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.75M

N/A

Employees

7

N/A

Net Income

-$1.99M

+10.3%

EBITDA

-$1.86M

+8.2%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$3.21M

+26.4%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-79.18%

N/A

Return on Invested Capital

-89.32%

N/A

Free Cash Flow

-$1.93M

+3.0%

Operating Cash Flow

-$1.93M

+3.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GBIOGeneration Bio Co.
$5.34+0.00%
SABSSAB Biotherapeutics, Inc.
$3.70+5.27%
VRCAVerrica Pharmaceuticals Inc.
$5.48-0.18%
EVAXEvaxion Biotech A/S
$3.00+2.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
UTZUtz Brands
$14.12+0.89%
JOBYJoby Aviation
$7.70+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.39+0.06%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.01+0.24%

Questions About NNVC

What is the current price of NanoViricides?

NanoViricides is trading at $1.68 per share.

What is the 52-week range for NanoViricides?

Over the past 52 weeks, NanoViricides has traded between $0.85 and $2.23.

How much debt does NanoViricides have?

As of the most recent reporting period, NanoViricides reported total debt of $0.00.

How much cash does NanoViricides have on hand?

NanoViricides reported $3.21M in cash and cash equivalents in its most recent financial results.

What is NanoViricides’s dividend yield?

NanoViricides does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services